Skip to content

Scholar Rock SRRK Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
Arrowhead Research logo
Arrowhead ResearchARWR
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$6.14B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's payments of debt issuance costs?
Scholar Rock (SRRK) reported payments of debt issuance costs of $1.31M in Q1 2026.